News from ionis pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 08, 2021, 07:05 ET Ionis prices private placement of convertible senior notes

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $550.0 million aggregate principal amount of 0% Convertible Senior Notes...

Apr 06, 2021, 16:36 ET Ionis announces proposed private placement of convertible notes

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million...

Apr 05, 2021, 07:05 ET Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of a Phase 3 clinical trial of ION363 in patients with amyotrophic lateral...

Mar 29, 2021, 07:05 ET Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that data from a Phase 2 clinical study of IONIS-PKK-LRx met its primary and secondary...

Mar 26, 2021, 07:05 ET Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in virtual...

Mar 22, 2021, 16:01 ET Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of...

Mar 01, 2021, 07:05 ET Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis

Ionis Pharmaceuticals (NASDAQ: IONS) today announced that the company has launched a new grant program that provides funding to U.S.-based...

Feb 24, 2021, 07:00 ET Ionis reports fourth quarter and full year 2020 financial results and recent business achievements

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter of 2020 and recent business highlights. "Last...

Feb 19, 2021, 07:05 ET Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in a virtual...

Feb 11, 2021, 07:05 ET Ionis to hold 2020 financial results webcast

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 24th at 9:00 a.m. Eastern Time to...

Jan 07, 2021, 17:30 ET Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical...

Jan 05, 2021, 20:38 ET Ionis to present at 39th Annual J.P. Morgan Healthcare Conference

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive...

Dec 17, 2020, 18:30 ET Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that its founder and executive chairman Stanley...

Dec 08, 2020, 21:15 ET Ionis highlights achievements, commercial strategy and technology advancements at Investor Day

At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) highlighted the company's significant achievements in 2020 and outlined its ...

Dec 02, 2020, 07:05 ET Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtual...

Dec 01, 2020, 17:10 ET Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with...

Dec 01, 2020, 07:05 ET Ionis to hold virtual investor day event

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live investor day webcast on Monday, December 7th at 11:00 a.m....

Nov 30, 2020, 17:15 ET Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of...

Nov 23, 2020, 17:15 ET Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational...

Nov 13, 2020, 07:05 ET Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new data for ION449, an investigational antisense medicine designed to reduce plasma...

Nov 12, 2020, 07:05 ET Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the upcoming presentations of clinical and non-clinical data for several of its...

Nov 10, 2020, 07:05 ET Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company's pioneering advancements in ...

Nov 09, 2020, 07:05 ET Ionis to present at upcoming virtual investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at...

Nov 04, 2020, 07:00 ET Ionis reports third quarter 2020 financial results and recent business achievements

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the third quarter of 2020 and recent business highlights. "We...

Oct 22, 2020, 07:05 ET Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that the first patients have been dosed with ION541 ...